Afinitor (Everolimus) 針對 ER+/HER2- 晚期乳癌經荷爾蒙治療失效病人之第三期臨床試驗
|
|
- Melanie Clarke
- 5 years ago
- Views:
Transcription
1 AGINITOR 標竿臨床試驗 1
2 RANDOMISATION (2:1) Afinitor (Everolimus) 針對 ER+/HER2- 晚期乳癌經荷爾蒙治療失效病人之第三期臨床試驗 BOLERO-2 Phase III: Everolimus + Exemestane in abc Eligibility Criteria (N = 724) Postmenopausal ER+ Unresectable locally advanced or MBC Recurrence or progression after LET or ANA EVE 10 mg PO daily + EXE 25 mg PO daily (n=485) Placebo PO daily + EXE 25 mg PO daily (n=239) PFS OS ORR Time to ECOG PS deterioration Safety QoL Stratification by Sensitivity to prior hormone therapy Visceral metastases Treatment until disease progression or unacceptable toxicity PO = orally; ECOG PS = Eastern Cooperative Oncology Group performance status; LET = letrozole; ANA = anastrozole; EVE = everolimus; EXE = exemestane Baselga et al. N Engl J Med Feb 9;366(6):520-9.
3 BOLERO-2: Baseline Characteristics Were Generally Balanced Between Arms Characteristic Everolimus + Exemestane (N = 485), % Placebo + Exemestane (N = 239), % Median age (range), years 62 (34, 93) 61 (28, 90) Race 即使內臟轉移, 只 Caucasian 要症狀不嚴重, 也 有機會從口服 Asian mtor 的治療組合 Performance status 0 中受益 Liver involvement Lung involvement Measurable disease a a All other patients had 1 bone lesion. Adapted from: Baselga J, et al. N Engl J Med. 2012;366(6):
4 Probability (%) of Event 研究結果證實 Afinitor (Everolimus) 可顯著延緩乳癌腫瘤惡化達 11 個月 BOLERO-2: Primary Endpoint, PFS (Central Assessment) HR = 0.38 (95% CI = 0.31, 0.48) Log-rank P <.0001 Everolimus + Exemestane: 11.0 mo (E/N = 188/485) 60 Placebo + Exemestane: 4.1 mo (E/N = 132/239) Number of patients still at risk Everolimus 485 Placebo Time, wk CI, confidence interval; E/N, patients with events/total patients; HR, hazard ratio; PFS, progression-free survival. Piccart-Gebhart M, et al. J Clin Oncol. 2012;30(suppl; abstr 559)(poster).
5 Afinitor (Everolimus) 可幫助 腫瘤縮小 & 穩定病情 BOLERO-2: Clinical Benefit Rate (Local Assessment) CBR, clinical benefit rate Piccart-Gebhart M, et al. J Clin Oncol. 2012;30(suppl; abstr 559)(poster).
6 Afinitor (Everolimus) 對患者 整體存活率有延長的趨勢 BOLERO-2: Overall Survival Was Numerically Better With Everolimus (Between-Group Differences Through 18 Months Median Follow-up) Interim Analysis (7-mo follow-up) 1 Updated Analysis (12.5-mo follow-up) 2 Final PFS Analysis (18-mo follow-up) 3 Cutoff date 11 Feb Jul Dec 2011 OS events (everolimus vs placebo) 83 (10.7% vs 13.0%) 137 (17.3% vs 22.7%) 200 (25.4% vs 32.2%) Δ OS events 2.3% 5.4% 6.8% Abbreviations: OS, overall survival; PFS, progression-free survival. 1. Baselga J, et al. N Engl J Med. 2012;366(6): ; 2. Hortobagyi G, et al. SABCS 2011, abstract S3-7; 3. Piccart M, et al. ASCO 2012, abstract
7 Probability of Event, % Afinitor (Everolimus) 可顯著延緩 患者生活品質惡化 BOLERO-2: Quality of Life Censoring times Everolimus + Exemestane (E/N = 254/485) Placebo + Exemestane (E/N = 113/239) P value = Time to Deterioration in QoL, wk Patients still at risk, n Eve+ Exe Placebo + Exe EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Core Cancer Quality of Life Questionnaire; E/N, patients with events/total patients; MID, minimal important difference; QoL, quality of life. Beck JT, et al. J Clin Oncol. 2012;30(suppl; abstr 539)(poster).
8 Afinitor (Everolimus) 再創乳癌標靶治療之新篇章! Monotherapy Combination chemotherapy Trastuzumab + chemotherapy HER2+ MBC Everolimus + exemestane (BOLERO-2) HR+/HER2- MBC Docetaxel Chan 1999 Doxorubicin Chan 1999 Paclitaxel Seidman 2004 Vinorelbine Muñoz 2006 Doxorubicin + paclitaxel Jassem 2001 Xeloda + docetaxel O Shaughnessy 2002 Gemcitabine + paclitaxel Albain 2004 FEC Zielinski 2005 Epirubicin + docetaxel Pacilio 2006 Trastuzumab + docetaxel Marty 2005 Docetaxel Marty 2005 Everolimus + exemestane BOLERO exemestane BOLERO Median PFS / TTP Time (months)
9 用法, 用量及副作用處理 9
10 劑型 用法用量及注意事項 劑型 癌伏妥 錠 5 毫克 衛署藥輸字第 號 用法用量 建議用量為 10 毫克 應於每天同一時間服用一次, 與食物或不與食物併服都可以 需以整杯水吞服整顆藥錠, 不可咀嚼或咬碎錠劑 用法用量 ( 續 ) 對無法吞服錠劑的患者, 應將 AFINITOR 錠劑以輕輕攪拌的方式完全溶散於一杯水 ( 約 30 毫升 ) 中, 並立即喝下 再於杯中倒入等量的水滌洗, 然後將滌洗液全部喝掉, 以確保服下完整的劑量 10
11 劑型 用法用量及注意事項 ( 續 ) 用法用量 ( 續 ) 應告知病患若忘記服用一劑 AFINITOR 時, 距離正常服藥時間 6 小時內仍可立即服一劑, 若超過 6 小時, 則應跳過這次劑量, 第二天再於正常服藥時間服用 AFINITOR 應警告病患不可服用二劑來補償忘記服用的劑量 11 劑量調整 出現嚴重和 / 或不耐受的不良反應 具肝功能不全患者 併用中效 CYP3A4 或 P-gP 抑制劑, 以及併用強效 CYP3A4 誘導劑時應適當調整劑量 禁忌 對於主成分 rapamycin 衍生物或任何賦形劑過敏者
12 特殊族群 腎功能不全的患者 Everolimus 大約有 5% 排泄至尿液中 在針對 170 名末期癌症受試者所進行的族群藥物動力學研究中, 未偵測到 everolimus 的 CL/F 對於肌酸酐廓清率 (25 至 178 毫升 / 分鐘 ) 有顯著影響 肝功能不全的患者 對於重度肝功能不全之荷爾蒙接受器呈陽性晚期乳癌患者, 若期望的益處超過風險時, 可降低 AFINITOR 的劑量使用 對於輕至中度肝功能不全患者, 建議調降劑量 12
13 特殊族群 ( 續 ) 年齡與性別的影響 在癌症受試者中進行的族群藥動學評估, 並未偵測到年紀或性別對 everolimus 的口服廓清率有顯著關聯性 疫苗接種 應告知病人避免接受活性疫苗注射或與接種活性疫苗的人進行緊密接觸 懷孕 懷孕分級 :D 應告知育齡婦女 AFINITOR 可能對胎兒造成傷害, 服用 AFINITOR 治療期間應採取有效之避孕措施並應持續至療程結束後 8 週 13
14 Potential Class Effects of mtor Inhibition Stomatitis Noninfectious pneumonitis Infections All Grades, % EVE + EXE (BOLERO-2)1 n=482 Hyperglycemia and hyperlipidemia Rash EVE + TAM (TAMRAD)2 n=54 TEM (Phase 3, RCC)3 n=208 Stomatitis 67a Rash Noninfectious 19b d pneumonitis Infections 50c Hyperglycemia 14 NR 26 Hyperlipidemia NR NR 27 a Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis, and lip ulceration. b Includes pneumonitis, interstitial lung disease, lung infiltration, and pulmonary fibrosis. c Includes all preferred terms within the infections and infestations system organ class. d Maroto JP, et al. J Clin Oncol. 2011;29(13): Retrospective analysis of 178 pts on TEM. 1. Afinitor (everolimus) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012; 2. Bachelot T, et al. J Clin Oncol. 2012;30(22): ; 3. Hudes G, et al. N Engl J Med. 2007;356(22): Images are not actual patients. 4
15 Stomatitis: Clinical Presentation mtor inhibitor-associated stomatitis 1,2 Distinct from chemotherapyinduced stomatitis Aphthous-like ulcers characterized by discrete, ovoid, superficial, well-demarcated ulcerations with a grayish-white pseudomembrane Ulcers typically develop acutely in the first cycle of therapy Severity usually peaks within the first 2 weeks of therapy Image reprinted from Porta C, et al. Eur J Cancer. 2011;47(9): de Oliveira MA, et al. Oral Oncol. 2011;47(10): ; 2. Wojtaszek C. Clin J Oncol Nurs. 2000;4(6): Images are not actual patients. 9
16 Stomatitis: Clinical Management Strategy Grade Symptoms Treatment and Management Everolimus Dose Modification 1 Minimal; can maintain normal diet 2 Symptomatic but can eat and swallow modified diet 3 Symptomatic and unable to adequately aliment or hydrate orally 4 Associated with life-threatening consequences Nonalcoholic or 0.9% salt water mouthwash several times daily Topical analgesic mouth treatments with or without topical corticosteroids Avoid agents containing hydrogen peroxide, iodine, and thyme derivatives Topical analgesic mouth treatments with or without topical corticosteroids Avoid agents containing hydrogen peroxide, iodine, and thyme derivatives Treat with appropriate medical therapy No change Temporarily interrupt dose until recovery to grade 1, then restart at same dose If stomatitis recurs at grade 2, then temporarily interrupt dose until recovery to grade 1, and restart at reduced dose Temporarily interrupt dose until recovery to grade 1, then restart at reduced dose Discontinue treatment Afinitor (everolimus) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Images are not actual patients. 12
17 Stomatitis: Patient Education Patient awareness and early intervention are important 1,2 Consider evaluation for herpesvirus or fungal infection 1 Oral hygiene: Educate patients about good oral hygiene 1,2 Rinse with nonalcoholic mouthwash Floss after each meal Use mild toothpaste and soft-bristled toothbrush Avoid agents containing alcohol, hydrogen peroxide, iodine, and thyme derivatives Note: Preventive treatment with sodium bicarbonate-based mouthwash has been shown to be ineffective 3 Advise patients to avoid foods that are spicy/acidic/salty 4 Prompt reporting: Advise patients to promptly report any signs or symptoms 1 >3 lesions Lesions lasting >3 days Lesions interfering with eating and drinking Porta C, et al. Eur J Cancer. 2011;47(9): ; 2. Pilotte AP, et al. Clin J Oncol Nurs. 2011;15(5):E83-E89; 3. Ferte C, et al. Eur J Cancer. 2011;47(15): ; 4. Eisen T, et al. J Natl Cancer Inst. 2012;104(2):
18 Rash: Clinical Presentation Drug-induced acneiform dermatitis 1 Can occur with mtor inhibitors and several other types of drugs (eg, corticosteroids, EGFR inhibitors, cyclosporine, anticonvulsants, anabolic steroids, azathioprine, and testosterone) Usually starts as an inflammatory lesion (papule or pustule); comedones (blackheads) may appear thereafter 1,2 Wide and unusual distribution typically found in acne-free areas (eg, upper extremities, trunk, neck) 1-4 Treatment includes topical treatments (with products containing corticosteroids, benzoyl peroxide, and antibiotics), systemic, antibiotics, and dose adjustments per PI. Images courtesy of Carmen Jacobs, RN, OCN; MD Anderson Cancer Center, Houston, TX. 1. Momin SB, et al. J Drugs Dermatol. 2010;9(6): ; 2. Mahe E, et al. Transplantation. 2005;79(4): ; 3. Plewig G, et al. Dermatology. 1998;196(1): ; 4. Mahe E, et al. J Am Acad Dermatol. 2006;55(1): Images are not actual patients. 23
19 Rash: Clinical Management Strategy Grade Symptoms Treatment and Management 1 Macular or papular eruption or erythema without associated symptoms 2 Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering <50% of body surface area 3 Severe, generalized erythroderma or macular, papular, or vesicular eruption; desquamation covering 50% of body surface area 4 Generalized exfoliative, ulcerative, or bulbus dermatitis Mild lesions may resolve spontaneously; no specific therapy Topical treatment with corticosteroids and products containing benzoyl peroxide and antibiotic initially Some patients with acne before starting everolimus benefit from topical as well as oral antibiotic therapy (i.e., tetracycline; avoid strong CYP3A4 inhibitors such as clarithromycin) Avoid retinoids as they may disrupt skin integrity and introduce risk for infection Everolimus Dose Modification No change If patient is able to tolerate the toxicity, maintain same dose If patient is unable to tolerate the toxicity, hold dose until recovery to grade 1, then restart at same dose If toxicity returns to grade 2, hold dose until recovery to grade 1, then restart at lower dose level Interrupt dose until recovery to grade 1, then restart at lower dose level Discontinue everolimus 1. Agricola K, et al. AANN 2011; Abstract P56 (poster); 2. Afinitor (everolimus) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012; 3. Moldawer NP, et al. Kidney Cancer J. 2010;8(2): Images are not actual patients. 12
20 Rash: Patient Education Inform patients that rash is a potential adverse event with everolimus use Advise patients not to use cosmetics containing retinoids Emphasize importance of prompt reporting of signs and symptoms 20
21 Hyperglycemia: Guidance for Practical Management Monitor fasting serum glucose levels before initiating everolimus therapy and periodically thereafter 1,2 Achieve optimal glycemic control before starting everolimus 1,2 Manage according to standard consensus guidelines 3 Grade Lab Values Treatment and Management 1 Glucose: >ULN-160 mg/dl (>ULN-8.9 mmol/l) 2 Glucose: > mg/dl ( mmol/l) 3 Glucose: > mg/dl ( mmol/l) 4 Glucose: >500 mg/dl (>27.7 mmol/l) Everolimus Dose Modification None No change Manage with appropriate medical therapy according to American Diabetes Association and European Association for the Study of Diabetes standard guidelines and monitor No dose adjustment required Temporary dose interruption until recovery to grade 1 Restart at a lower dose Discontinue everolimus 1. Afinitor Summary of Product Characteristics. West Sussex, UK: Novartis Europharm Ltd.; 2012; 2. Eisen T, et al. J Natl Cancer Inst. 2012;104(2):93-113; 3. Nathan DM, et al. Diabetes Care. 2009;32(1):
22 Inhibition of PI3K/AKT/mTOR Signaling Affects Glucose Homeostasis and Fat Metabolism mtor is downstream effector of insulin signaling and subsequent gluconeogenesis, glycogen synthesis, and lipogenesis As a consequence, mtor inhibition can disrupt these physiologic processes to varying degrees Hyperglycemia and hyperlipidemia are both known AEs that can occur with everolimus use 22
23 How to address the diagnosis of noninfectious pneumonitis? Baseline imaging (chest x-ray) before starting everolimus is key Consider the patient s risk for infection or malignancy in the chest Attend to new or worsening respiratory symptoms Differential diagnosis and a multidisciplinary approach is important (pulmonologist, infectious disease specialist) 23
24 Noninfectious Pneumonitis: Clinical Management Strategy Grade Symptoms Treatment and Management Everolimus Dose Modification 1 Asymptomatic No specific therapy Initiate appropriate monitoring 2 Symptomatic, not interfering with ADL Depending on severity of symptoms: Consider consulting a pulmonologist Consider diagnostics to exclude infectious causes Consider corticosteroids No change required Consider dose interruption until recovery to grade 1, restart at a lower dose Discontinue treatment if failure to recover within 4 weeks 3 Symptomatic, interfering with ADL, O2 required 4 Life threatening, ventilatory support indicated Consult a pulmonologist Perform diagnostics to exclude infectious causes If infectious cause excluded, consider use of corticosteroids In presence of impending respiratory distress: consider use of concomitant corticosteroids and antibiotics Dose interruption until recovery to grade 1, consider restarting everolimus at a lower dose If toxicity recurs at grade 3, consider discontinuation Discontinue everolimus 1. Adapted from Porta C, et al. Eur J Cancer. 2011;47(9): ; 2. Moldawer NP, et al. Kidney Cancer J. 2010;8(2):51-59; 3. Eisen T, et al. J Natl Cancer Inst. 2012;104(2):93-113; 4. Afinitor (everolimus) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;
25 Noninfectious Pneumonitis: Patient Education Advise patients to promptly report any new or worsening respiratory symptoms Shortness of breath Cough Fever 25
26 Hepatitis B Virus Reactivation: Clinical Management Strategy PI3K/mTOR pathway activation has been associated with suppressed HBV viral replication; thus, mtor inhibition may trigger HBV replication and the process of viral reactivation 1 Baseline Results Reactivation Definition Management Resolution Positive HBV DNA OR Positive HBsAg Negative HBV DNA and HBsAg AND Positive HBsAb (with no history of vaccination against HBV) OR Positive HBcAb Increase of 1 log in HBV DNA relative to baseline HBV DNA value OR New appearance of measurable HBV DNA New appearance of measurable HBV DNA Start a second antiviral AND Interrupt everolimus administration until resolution ( baseline HBV DNA levels) Start first antiviral medication AND Interrupt everolimus administration until resolution (negative HBV DNA levels) 28 days: restart everolimus at one dose lower If patient is already receiving the lowest dose, restart at the same dose after resolution >28 days, discontinue everolimus Continue antiviral therapy at least 4 weeks after last dose of everolimus 1. Guo H, et al. J Virol. 2007;81(18):
27 GENERAL GUIDANCE ON EVEROLIMUS DOSE MODIFICATIONS 27
28 Everolimus Dose Modifications for AEs Management of AEs may require temporary dose reduction and/or interruption Grade Everolimus Dose Modification 1 Mild Treat according to best clinical practice No specific dose modifications are needed 2 Moderate a Interrupt everolimus until recovery to grade 1 Restart everolimus at the same dose 3 Severe a Interrupt everolimus until recovery to grade 1 Restart everolimus at the next lower dose level 4 Debilitating b Discontinue everolimus a For stomatitis, pneumonitis, and other toxicities. b For stomatitis and pneumonitis. Afinitor (everolimus) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;
29 Everolimus Dose Modifications for Hepatic Impairment Dose reductions are recommended for patients with hepatic impairment Child-Pugh Class Everolimus Dose Modification 1 Mild Suggested dose is 7.5 mg/day Dose can be further reduced to 5 mg/day if not well tolerated 2 Moderate Suggested dose is 5 mg/day Dose can be further reduced to 2.5 mg/day if not well tolerated 3 Severe If desired benefit outweighs the risk, suggested dose is 2.5 mg/day This dose should not be exceeded Afinitor (everolimus) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;
30 Everolimus Dose Modifications for Drug-Drug Interactions Avoid use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) Be cautious when using moderate CYP3A4 and/or P- glycoprotein inhibitors (eg, amprenavir, fosamprenavir, aprepitant, erythromycin, fluconazole, verapamil, diltiazem) If coadministration is necessary, reduce dose to 2.5 mg/day Avoid use of strong CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) If coadministration is necessary, increase dose to 20 mg/day 30
31 31
32 32
Uncertainty of Measurement Application to Laboratory Medicine 鏡檢組 蔡雅雯 2014/09/09
Uncertainty of Measurement Application to Laboratory Medicine 鏡檢組 蔡雅雯 2014/09/09 Objectives Definitions Methodology Equation of Measurement Uncertainty Measurement Uncertainty Goal Examples Uncertainty
More information乳癌化療指引. Breast Cancer
乳癌化療指引 103 年 12 月第五版 99-102 年, 第一至四版 注意事項 : 本院癌症團隊基於實證醫學制定此化學治療指引 : 本院癌症團隊基於實證醫學制定此化學治療指引, 實證醫學之結論源自臨床詴驗, 實證醫學之結論源自臨床詴驗, 惟參與臨床詴驗之研究對象多以 70 歲以下之病人為主, 故建議 70 歲以上病人接受治療時, 應依據病人實際臨床狀況進行抗癌藥物劑量之調整! 健保藥品給付限制註記說明
More information乳癌化療指引. 104 年 12 月第六版 年,1 st - 5 th 版
乳癌化療指引 104 年 12 月第六版 99-103 年,1 st - 5 th 版 注意事項 : 本院癌症團隊基於實證醫學制定此化學治療指引 : 本院癌症團隊基於實證醫學制定此化學治療指引, 實證醫學之結論源自臨床試驗, 實證醫學之結論源自臨床試驗, 惟參與臨床試驗之研究對象多以 70 歲以下之病人為主, 故建議 70 歲以上病人接受治療時, 應依據病人實際臨床狀況進行抗癌藥物劑量之調整! 健保藥品給付限制註記說明
More information荷爾蒙補充療法及癌症 Hormone Replacement Therapy and Cancers 黃思誠 台大醫院婦產科
荷爾蒙補充療法及癌症 Hormone Replacement Therapy and Cancers 黃思誠 台大醫院婦產科 停經後的荷爾蒙補充療法 (HRT) 可以治療停經後症候群, 如潮紅 心悸 失眠等, 也可以防止及治療骨質疏鬆 常用藥物口服動情激素 ( 如 premarin), 經皮膚吸收動情激素 (estradiol) 黃體素 ( 如 provera) 動情激素及黃體素混合經皮膚吸收劑 動情激素及
More information如果你有過造影劑過敏 對於術前用藥, 你需要知道些什麽
UW MEDICINE PATIENT EDUCATION IF YOU HAVE HAD CONTRAST ALLERGY CHINESE 如果你有過造影劑過敏 對於術前用藥, 你需要知道些什麽 本資料是爲某些病人編寫, 這些病人過去在接受造影劑時出現過中等程度或嚴重的過敏反應, 而現在已預約接受使用造影劑的造影研究 你的醫生已經決定需爲你做一項特殊的造影研究, 藉以幫助他們管理你的健康 已爲你安排好做以下其中一項掃描
More information乳癌檢驗 面面觀 熊維嘉
乳癌檢驗面面觀 熊維嘉 30 4 2011 乳癌檢驗面面觀 Tissue diagnosis Imaging 抽組織 醫學影像 Blood test 抽血 香港癌症資料統計中心 2007 37% increase over 15 years 年齡別發生率 age-specific incidence rate (per 100 000 women) 180 160 140 120 100 80 60
More information大舜政策研究中心 Dashun Policy Research Centre Ltd Annual Conference 2012
香港樂健會社 Happy Health Society in association with 大舜政策研究中心 Dashun Policy Research Centre Ltd Annual Conference 2012 人人健康由我做起 中西結合預防癌症 Prevention of Cancer East Meets West Approaches 2012 年 12 月 22 日 ( 星期六
More informationA cost benefit analysis of weight management strategies
74 Asia Pac J Clin Nutr 2006;15 (Suppl): 74-79 Original Article A cost benefit analysis of weight management strategies Jodie Yates and Chris Murphy Econtech Over the past twenty years, obesity has become
More information多國或衛生組織的建議 英國科學諮詢委員會 - 營養 : 美國 / 加拿大營養師協會 國際脂類研究社 : Recommendations of National or Health Organizations
Recommendations of National or Health Organizations 多國或衛生組織的建議 Australia and New Zealand National Health and Medical Research Counci 澳大利亞和新西蘭國家衛生與醫學研究委員會 : World Health Organization 世界衛生組織 : Dutch Health
More informationCase Conference. Basic Information. Chief Complaint PMH PDH. 2013/06/22 台南奇美醫院 Reporter: 黃鈺芬醫師. Gender: female Age: 68 y/o Attitude: philosophical
Case Conference Basic Information 2013/06/22 台南奇美醫院 Reporter: 黃鈺芬醫師 Gender: female Age: 68 y/o Attitude: philosophical Chief Complaint Pus discharge over upper anterior area for several days PMH PDH Hypertension
More informationClinical Scenario. L1 laminectomy and decompression T11-12, L2-3 posterior instrumented fusion L1 vertebroplasty
骨科 R1 蔡沅欣 2013.3.18 Clinical Scenario 82 y/o male Fell down about 3 months ago, no significant discomfort, except mild back pain In recent 2 months, back pain progressed, bilateral lower leg weakness and
More information子宮頸癌. Cervical Cancer 三軍總醫院 余慕賢
子宮頸癌 Cervical Cancer 三軍總醫院 余慕賢 96 台灣女性 10 大癌症 ( 發生率排序 ) 乳癌 7,502 66.10 結腸癌 4,471 39.39 肺癌 3,161 27.85 肝癌 2,900 25.55 子宮頸癌 1,749 15.41 甲狀腺癌 1,407 12.40 胃癌 1,301 11.46 子宮體癌 1,165 10.26 皮膚癌 1,113 9.81 卵巢癌
More information運用運動訓練維持失智老人如廁功能之探討 陳昱合張素嫺 * 方妙君 ** 蔡美利 *** 關鍵詞 : 如廁功能 失智老人 運動計畫 Chen et al., Carpenter, Hastie, Morris, Fries, & Ankri,
265 運用運動訓練維持失智老人如廁功能之探討 陳昱合張素嫺 * 方妙君 ** 蔡美利 *** 無法自行如廁被視為失智老人日常生活活動功能邁入嚴重依賴的關鍵之一 然而目前缺乏一個以理論為基礎的照護措施來維持或促進老人如廁功能, 繼而延緩依賴程度 運動訓練介入後, 對失智老人如廁行為能力之探討 運動介入措施設計是以 Bandura 的社會認知理論為基礎, 執行為期 8 週的步行及下肢負重運動訓練 本研究採單組
More informationFIRMAGON (Degarelix) a new-generation GnRH antagonist for advanced hormone-dependent prostate cancer. 20/04/2016 Jeffrey Hsiao 蕭哲文
FIRMAGON (Degarelix) a new-generation GnRH antagonist for advanced hormone-dependent prostate cancer 20/04/2016 Jeffrey Hsiao 蕭哲文 Background to Androgen Deprivation Therapy (ADT) in Prostate Cancer Testosterone
More information愛滋病照護 性別觀點 柯乃熒 國立成功大學醫學院護理系副教授暨國立成功大學附設醫院護理部督導長 21: HIV
22 愛滋病照護 性別觀點 柯乃熒 國立成功大學醫學院護理系副教授暨國立成功大學附設醫院護理部督導長 摘要 : 生理 社會及文化中不平等的性別權力關係, 增加女性及青少女感染愛滋病毒的風險 抗愛滋 病毒藥物治療能有效抑制愛滋病毒複製, 延長愛 滋感染者之預期壽命 愛滋病毒感染已成為慢性 病, 倘若協助女性感染者規則回診及接受治療, 抗病毒藥物治療的效果及因愛滋病死亡的比率並 無顯著性別差異, 加上人工生殖技術的成熟,
More information限制水分飲食需要遵循的指引 你的醫生已經要你實行限制水分飲食 有些食物算作水分 有些食物看上去不像水分, 但是仍然需要將其算作你的水分攝入量的一部分 這是因爲 :
UW MEDICINE PATIENT EDUCATION FLUID-RESTRICTED DIET CHINESE 限制飲食需要遵循的指引 本手冊給出限制飲食的基本指引 它包括一份食物清單 ( 這些食物應該算作攝入量的一部分 ), 以及幫助控制的提示 你的醫生已經要你實行限制飲食 你在 24 小時中只可以喝 毫升 (ml) 的水 即大約 盎司 (oz), 或者 杯水 繼續進行這種限制性飲食, 直到你的醫生說你可以恢復你平常所喝的水量爲止
More informationModule: Hope and Optimism. Hope
Module: Hope and Optimism Hope In a nutshell: Cognitive theory of hope (C.R. Snyder, 2002) denotes that a person with high hope is able to use various pathways or waypower to achieve goals. Throughout
More informationTotal knee arthroplasty for primary knee osteoarthritis: changing pattern over the past 10 years
O R I G I N A L A R T I C L E CH Yan KY Chiu FY Ng 忻振凱曲廣運吳富源 Total knee arthroplasty for primary knee osteoarthritis: changing pattern over the past 1 years CME Objective To review the epidemiology of
More information行政院國家科學委員會專題研究計畫期中進度報告
行政院國家科學委員會專題研究計畫期中進度報告 CD8 T 細胞在對胞內菌保護性免疫反應的角色 (2/3) 計畫類別 : 個別型計畫計畫編號 : NSC91-2320-B-002-096- 執行期間 : 91 年 08 月 01 日至 92 年 07 月 31 日執行單位 : 國立臺灣大學醫學院免疫學研究所 計畫主持人 : 伍安怡 報告類型 : 精簡報告 處理方式 : 本計畫可公開查詢 中華民國 92
More informationClinical characteristics. Nutritional Management of Nephrotic syndrome 陳淑子. Causes. Medical Nutrition therapy
Nutritional Management of Nephrotic syndrome 陳淑子 臺北醫學大學保健營養學系助理教授台灣營養學會臨床營養委員會腎臟專科小組召集人 1 Clinical characteristics Proteinuria Hypoalbuminemia Edema Hyperlipidemia Hypercoagulability Abnormal Bone metabolism
More informationCase-control study of Sichuan and Hong Kong children with melamine-associated renal stones: renal ultrasonography and urinary IL-8 and MCP-1 levels
Title Case-control study of and children with melamine-associated renal stones: renal ultrasonography and urinary IL-8 and MCP-1 levels Author(s) Lau, YL; Tu, W Citation Medical Journal, 213, v. 19 n.
More informationCOPD 的慢性照護邁向全人醫療 時間 : 民國 102 年 9 月 15 日地點 : 高雄長庚紀念醫院兒童醫院 6 樓紅廳主辦 : 台灣慢性阻塞性肺病學會講師 : 彰基胸腔科林慶雄主任.
COPD 的慢性照護邁向全人醫療 時間 : 民國 102 年 9 月 15 日地點 : 高雄長庚紀念醫院兒童醫院 6 樓紅廳主辦 : 台灣慢性阻塞性肺病學會講師 : 彰基胸腔科林慶雄主任 E-mail : 47822@cch.org.tw Speech Outline 1 COPD Care Gap 2 Current Guideline 3 Integrated Care Model 4 Future
More information認識非小細胞肺癌 為肺癌患者傳送呼吸希望. Understanding Non-Small Cell Lung Cancer. Sending a breath of hope to all of those touched by lung cancer
認識非小細胞肺癌 Understanding Non-Small Cell Lung Cancer 為肺癌患者傳送呼吸希望 Sending a breath of hope to all of those touched by lung cancer 呼吸希望 對於肺癌患者來說, 通往疾病緩解之路艱辛漫長 對於他們, 每次呼吸都是如此珍貴 如此難得, 每次呼吸都是生存的希望 醫學昌明, 使得患者可以與肺癌共存,
More informationThe Role of Herbal Medication in Poor TACE Response Hepatocellular Carcinoma:
DOI 10.3966/181020932017121504006 Case Report The Role of Herbal Medication in Poor TACE Response Hepatocellular Carcinoma: Case Report Chao-Hua Fang 1, Chin-Chuan Tsai 1,2, Chien-Lin Chen 3, Jiann-Hwa
More informationBayesian Trail Design 貝式試驗設計
北院區臨床試驗中心生物統計組 Biostatistics Unit Clinical Trial Center, CGMH Bayesian Trail Design 貝式試驗設計 Lan-Yan Yang, PhD ( 楊嵐燕 ) 2018/03/05 1 Contents 1 Motivation 2 Bayesian methods 3 Examples 4 Considerations and
More informationInvestigation of Fitness Education Model s Implementation Effects
Journal of National Taipei Teachers College, Vol.7, No. (Mar. ) 7~8 NATIONAL TAIPEI TEACHERS COLLEGE 7 Investigation of Fitness Education Model s Implementation Effects Min-hua Chung * ABSTRACT The main
More informationEssential Biochemistry
Essential Biochemistry Third Edition Charlotte W. Pratt Kathleen Cornely Lecture Notes for Chapter 14 The Citric Acid Cycle The citric acid cycle Citric acid cycle (TCA cycle; Kerbs cycle) is a central
More informationAntigen Recognition by B-cell and T-cell Receptors
Antigen Recognition by B-cell and T-cell Receptors 第 4 章 Outlines: Antibody, TCR, and MHC 1. The structures and functions of antibodies, including variable and constant domains, antigen binding sites.
More informationBrugada Syndrome in the Elderly in Taiwan Report of Two Cases
Case Report Acta Cardiol Sin 2005;21:62 7 Brugada Syndrome in the Elderly in Taiwan Report of Two Cases Jyh-Ming Juang, Ling-Ping Lai, Jiunn-lee Lin and Fu-Tien Chiang Brugada syndrome is a potentially
More informationMedical Treatment for Osteoporosis ~From today to tomorrow. Presented by 劉明村
Medical Treatment for Osteoporosis ~From today to tomorrow Presented by 劉明村 Miacalcic Qualitative Effects of Salmon Calcitonin Therapy (QUEST) NIH Definition of Osteoporosis Osteoporosis is defined as
More information財團法人明日醫學基金會研究計畫申請書. Yao-Chun Hsu 高雄市燕巢區義大路 1 號 1 月 1 日起至 101 年 12 月 31 日止
財團法人明日醫學基金會研究計畫申請書 計畫名稱 ( 中文 ) 決定慢性 B 型肝炎嚴重急性發作預後的病毒相關因子 ( 英文 ) Viral factors in determining outcomes of chronic hepatitis B patients with severe acute exacerbation 計畫類別 個別型 整合型 計畫歸屬 基礎醫學 生物醫學 臨床醫學 資訊系統
More informationMechanism Action of Escin
3 Mechanism Action of Escin Reduces Permeability of Capillaries Inhibit lysosomal activity and stabilize lysosomal membrane Hinder the metabolism of protease Reduce permeability of capillaries Capillary
More informationEffect of Alendronate and Teriparatide on Bone Mineral Density in Postmenopausal Women
35 Original Article Effect of Alendronate and Teriparatide on Bone Mineral Density in Postmenopausal Women Pei-Tsen Chen, Piya-on Numpaisal, 2 Ching-Chuan Jiang, Hongsen Chiang Departments of Physical
More informationSurveillance and outcome of liver metastasis in patients with colorectal cancer who had undergone curative-intent operation
O R I G I N A L A R T I C L E KC Cheng YP Yeung Patrick YY Lau William CS Meng 鄭繼志楊玉鵬劉應裕蒙家興 Surveillance and outcome of liver metastasis in patients with colorectal cancer who had undergone curative-intent
More information全民健康保險研究資料庫在急診醫療利用分析之應用
全民健康保險研究資料庫開發與應用研討會 全民健康保險研究資料庫在急診醫療利用分析之應用 翁瑞宏 嘉南藥理科技大學醫管系暨碩士班助理教授 黃金安 台中榮民總醫院急診醫學科主任 2009 年 9 月 3 日 Outline Jin-An Huang, Rhay-Hung Weng, Wen-Chen Tsai, Wei-Hsiung Hu and Dar-Yu Yang, Analysis of Emergency
More informationNeoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer
ORIGINAL ARTICLE Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer Vivian CM Man, Polly SY Cheung * This article was published on 9 May 2017 at www.hkmj.org.
More informationEvolution of Shock Monitoring and ICU Scoring. NTUH Anesthesiology/SICU Yeh
Evolution of Shock Monitoring and ICU Scoring NTUH Anesthesiology/SICU Yu-Chang Yeh Shock 組織灌流不足 (Hypoperfusion) 氧氣供應不足 / 無法利用 休克重要觀念 血壓 115/40 (65) mmhg, 有沒有休克? Usual BP 185/95 CAD ICP = 30 mmhg IAP =
More informationA Sustainable Hospitalcommunity. Programme for Orthopaedic Patients with Chronic Pain Syndrome
A Sustainable Hospitalcommunity Partnership Programme for Orthopaedic Patients with Chronic Pain Syndrome Cheung KK 1 Chan PH 1 Chow YY 1 Hung ATF 2 Ho JPS 2 Tse A 1 Chan I 1 Ip A 1 Wong C 1 Fung C 1 Kwok
More informationPeritoneal Dialysis in End-Stage Renal Disease Patients with Liver Cirrhosis and Ascites
Peritoneal Dialysis in End-Stage Renal Disease Patients with Liver Cirrhosis and Ascites Chien-Lung Chen 1, Hang-Lung Chang 2, Ju-Yu Wang 3, Chin-Pyng Wu 4 Abstract End-stage renal disease (ESRD) patients
More informationCancer Biology Course
Cancer Biology Course Tumor suppressor and Apoptosis: Master Guardian and Executioner 徐欣伶 (Hsin-Ling Hsu) hsinling88@nhri.org.tw 國家衛生研究院 03/31/2016 本簡報內容部份取材自 Garland Science, Taylor & Francis Group 出版社所出版之
More informationDelayed presentation of symptomatic breast cancers in Hong Kong: experience in a public cancer centre
O R I G I N A L A R T I C L E Delayed presentation of symptomatic breast cancers in Hong Kong: experience in a public cancer centre TK Yau CW Choi Esther Ng Rebecca Yeung Inda S Soong Anne WM Lee 游子覺蔡卓偉吳如花楊美雲宋崧李詠梅
More informationFeasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma
Original Article Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma Sonia YP Hsieh, Danny TM Chan *, Michael KM Kam, Herbert HF Loong, WK Tsang, Darren
More informationGERD. From Clinician to Pharmacologist. Chien-Heng, Shen
GERD From Clinician to Pharmacologist Chien-Heng, Shen 2014.9.24 Gastroesophageal Reflux Disease (GERD) when the reflux of gastric content causes troublesome symptoms or complications Esophageal Syndromes
More informationClinical Nursing Application of Tidal Peritoneal Dialysis
Clinical Nursing Application of Tidal Peritoneal Dialysis 高雄長庚醫院腹膜透析室 郭麗雀 PD catheter implantation This 76 years old male has history of ESRD and initiated CAPD since 2005 PD catheter was implanted on
More information20 December 2018 Ms. M Y Kong (CICO Office)
20 December 2018 Ms. M Y Kong (CICO Office) 1 Purpose 目的 To provide and elaborate HA TFIC s recommendations on immunization requirement for volunteers in HA hospitals. 提供及詳述醫管局感染控制專責小組對醫管局轄下義工免疫要求的建議 2
More informationSurgical Ligation of Patent Ductus Arteriosus in Extremely Low Birth Weight Premature Neonates
Original Article Acta Cardiol Sin 005;1:0 4 Congenital Heart Disease Surgical Ligation of Patent Ductus Arteriosus in Extremely Low Birth Weight Premature Neonates Haw-Kwei Hwang, 1 Ming-Ren Chen, 1,4
More informationSSM Wong, K Wang, EHY Yuen, JKT Wong, A King, AT Ahuja
Hong Kong J Radiol. 2011;14:155-60 ORIGINAL ARTICLE Visual and Quantitative Analysis by Gallium-67 Single-photon Emission Computed Tomography/Computed Tomography in the Management of Malignant Otitis Externa
More information戒菸治療新進展 郭斐然 臺大醫院家庭醫學部
戒菸治療新進展 郭斐然 臺大醫院家庭醫學部 今天的議題 Varenicline 對精神病患之安全性 尼古丁代謝與戒菸治療之研究 Part One Varenicline 對精神病患之安全性 輝瑞公司加註的警語 曾有接受 Champix 治療的病人發生嚴重的神經精神症狀 有些停止吸菸病患因發生尼古丁戒斷症狀而使評估複雜化, 然而有些症狀仍發生在繼續吸菸的病人身上 所有正在接受 Champix 治療的病患應觀察其精神症狀,
More informationA Case Report of Hypotension and Bradycardia Associated with Immediate-Release Diltiazem Overdose
Formosa Journal of Clinical Pharmacy 臺灣臨床藥學雜誌 Vol. 18. No. 1 2010. pp. 85-92 第 18 卷第一期 案例報告 A Case Report of Hypotension and Bradycardia Associated with Immediate-Release Diltiazem Overdose Li-Yao Lee
More informationAlleviating Cancer Pain Toward Better Quality of Life
Alleviating Cancer Pain Toward Better Quality of Life 林至芃醫師 台大醫院麻醉部疼痛科科主任台大醫院麻醉部暨腫瘤醫學部合聘主治醫師台大醫學院醫學系臨床助理教授台灣疼痛醫學會秘書長 82 y/o male Newly diagnosed PC Initial presentation Back pain Shoulder pain Rapid progressed
More informationEBM 月會. Evidence-Based Medicine. Reporter: R1 丁楷庭 DATE: 101/03/05
EBM 月會 Evidence-Based Medicine Reporter: R1 丁楷庭 DATE: 101/03/05 Clinical scenario-1 A 61 year-old female patient Operation History: left thigh lipoma status post excision 10+ years ago at YUAN S General
More informationName (Block Letters) (In Chinese) (HKID No.)
Undertaking in respect of Patient Management in Name (Block Letters) (In Chinese) (HKID No.) 1. I have read the Protocol for Patient Management in ( Protocol ) and Guidelines of management of patient with
More informationCisplatin plus Vinorelbine (PVn) as A Palliative Regimen Beyond Second Line for Advanced Breast Cancer A Single Institute Experience
內科學誌 20:22:344-35 Cisplatin plus Vinorelbine (PVn) as A Palliative Regimen Beyond Second Line for Advanced Breast Cancer A Single Institute Experience Yi-Feng Wu, Tso-Fu Wang, Sung-Chao Chu, Kuan-Po Huang,
More informationEtiologies of Malnutrition in ESRD
透析患者常見的營養問題與飲食治療 彰化基督教醫院 陳虹霖營養師 Etiologies of Malnutrition in ESRD Decreased intake -anorexia -loss of taste - gastroparesis - medications - dietary restrictions - depression Inter-current illnesses Metabolic
More information兒童及青少年肥胖評估工具 黃秀玫張碧真 * Cole & Rolland-Cachera, body mass index, BMI Mei et al., 2002 BMI. body mass index, BMI BMI
78 兒童及青少年肥胖評估工具 黃秀玫張碧真 * 身體組成的測量可以觀察身體的相關生長與疾病的狀態, 臨床與研究上常運用各種測量方式以定 義兒童及青少年肥胖 本文主要回顧實地測量方 式, 探討各種工具的運用與信 效度, 並以臺 灣實施現況加以討論, 以期在未來可以正確地評 估兒童及青少年肥胖 測量身體組成的方式包括 實驗室檢查法與實地測量法, 其中實地測量法包 括重高指標與脂肪分佈的測量, 而實地測量方式
More information37th Annual J.P. Morgan Healthcare Conference January 9, 2019
台灣浩鼎生技股份有限公司 腫瘤免疫與標靶抗癌療法全球創新者 黃秀美總經理 37th Annual J.P. Morgan Healthcare Conference January 9, 2019 This presentation contains certain forward-looking statements. Safe Harbor Statement These forward-looking
More informationImplementation of the Care Model for Pediatric Asthma. Loretta Au, MD Chief of Pediatrics Charles B. Wang Community Health Center May 2, 2007
Implementation of the Care Model for Pediatric Asthma Loretta Au, MD Chief of Pediatrics Charles B. Wang Community Health Center May 2, 2007 Goal of this talk Share experience/lessons learned of the Charles
More informationExtra-corporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: A Single Center Experience
Original ECMO for ARDS Acta Cardiol Sin 2007;23:97 02 Extra-corporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: A Single Center Experience Shye-Jao Wu, Ming-Ren Chen, Shen Sun, Jiun-Yi
More informationBreast Pathway Group Everolimus in Advanced Breast Cancer
Breast Pathway Group Everolimus in Advanced Breast Cancer Indication: Hormone receptor positive, HER2 negative advanced breast cancer National Cancer Drug Fund criteria: ER+ve, HER2 ve metastatic breast
More information流行性感冒 Q&A ( 年冬天 ) Influenza Q&A (for winter)
頁編號 : 1 / 7 流行性感冒 Q&A (2014-2015 年冬天 ) Influenza Q&A (for 2014-2015winter) 1. 甚麼是流行性感冒? 1. What is Influenza? 答 : 流行性感冒, 簡稱流感, 是一種由 流感病毒引起的急性呼吸道傳染病 A: Influenza, also known as the flu, is an acute contagious
More informationIntroduction CME. KY Lo *, CK Chan
CME Original Article Characteristics and outcomes of patients with percutaneous coronary intervention for unprotected left main coronary artery disease: a Hong Kong experience KY Lo *, CK Chan This article
More informationWhite Paper. Study to Demonstrate Efficiency of Sharpness Recovery. No Revision A 作成 : 2016 年 8 月 EIZO 株式会社企画部商品技術課
White Paper Study to Demonstrate Efficiency of Sharpness Recovery No.16-001 Revision A 作成 : 2016 年 8 月 EIZO 株式会社企画部商品技術課 White Paper (Q16B014-AS-10001A) 1/3 医用モニターには高輝度タイプの液晶パネルが広く使われているが 液晶パネルの開口率を大きくすることが高輝度を実現する手段の
More informationName: Hsu, Hsien-Yeh ( 許先業 )
Name: Hsu, Hsien-Yeh ( 許先業 ) 教授, 國立陽明大學醫學生物技術暨檢驗學系 Email: hsienyeh@gmail.com EDUCATION AND POSITIONS HELD: Education: Taiwan University (Taiwan) Bachelor 1971~1975 Agriculture Chemistry Cornell University
More informationDistraction Histiogenesis for the Treatment of Lichtman Stage II Kienböck s Disease: A Case Report
Tungs Medical Journal 11 (2017) 39-43 39 Case Report Distraction Histiogenesis for the Treatment of Lichtman Stage II Kienböck s Disease: A Case Report Wei Cheng Lai, Sheng Chieh Lin, Hung Kai Lo* Department
More information1.0 RISPERDAL CONSTA (risperidone powder and solvent for prolonged-release suspension for intramuscular injection) Global Updated Quality Dossier Heal
1.0 RISPERDAL CONSTA (risperidone powder and solvent for prolonged-release suspension for intramuscular injection) Global Updated Quality Dossier Health Authority Reviewer Guide INTRODUCTION RISPERDAL
More information選擇性第一到第三區頸部淋巴廓清之最低淋巴摘除數量
Head & Neck-01 選擇性第一到第三區頸部淋巴廓清之最低淋巴摘除數量 Minimal Lymph Node Yield in Elective Level I-III Neck Dissection Jason D. Pou, MD; Blair M. Barton, MD; Claire M. Lawlor, MD; Christopher H. Frederick, BS; Brian
More informationThe Abuse of Plasticisers in Food
在食物中濫用塑化劑 The Abuse of Plasticisers in Food 1 今年五月二十三日, 台灣食品藥物管理局 ( 管理局 ) 公布, 驗出 16 款飲品濫用了塑化劑鄰苯二甲酸二 (2- 乙基己酯 ) (DEHP) 其後, 台灣當局查出更多食物含有 DEHP, 以及其他塑化劑, 包括鄰苯二甲酸二異壬酯 (DINP) 及鄰苯二甲酸二正丁酯 (DBP) 調查工作顯示, 有關產品含塑化劑是由於非法使用含塑化劑的起雲劑引致
More informationHorng-Yih Ou, Shu-Hwa Hsiao*, Eugene Hsin Yu, and Ta-Jen Wu
Etiologies and Clinical Manifestations of Hyperprolactinemia in A Medical Center in Southern Taiwan Horng-Yih Ou, Shu-Hwa Hsiao*, Eugene Hsin Yu, and Ta-Jen Wu Department of Internal Medicine, *Department
More information結核病的診斷與治療 高醫附設醫院感染內科 盧柏樑醫師
結核病的診斷與治療 高醫附設醫院感染內科 盧柏樑醫師 結核病 ~ 三千年歷史的古老疾病 埃及時代 西元前 3700-1000 年 土偶 木乃伊 (Nesperhan, priest of Amun) Primary TB Active TB 10% 有症狀有傳染性 Latent TB Latent TB 90% Active TB disease Latent TB infection progresses
More informationAn original discovery: selenium deficiency and Keshan disease (an endemic heart disease)
320 Asia Pac J Clin Nutr 2012;21 (3):320-326 Review An original discovery: selenium deficiency and Keshan disease (an endemic heart disease) Junshi Chen MD Institute of Nutrition and Food Safety, Chinese
More informationIMPLEMENTING THE CDC S COLORECTAL CANCER DEMONSTRATION PROGRAM:
IMPLEMENTING THE CDC S COLORECTAL CANCER SCREENING DEMONSTRATION PROGRAM: WISDOM FROM THE FIELD Rohan EA et al., Cancer 2013;119(15 suppl):2870-83 LEO CHAN 24 AUG 2013 BACKGROUND Colorectal Cancer (CRC)
More information內文 : INDICATIONS AND BENEFITS OF BISPHOSPHONATE THERAPY
原文題目 ( 出處 ): 原文作者姓名 : 通訊作者學校 : 報告者姓名 ( 組別 ): American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg
More informationDEFINITION OF COPD IS A DISEASE STATE CHARACTERIZED BY AIRFLOW LIMITATION THAT IS NOT FULLY REVERSIBLE.
DEFINITION OF COPD CHRONIC OBSTRUCTIVE PULMONARY DISEASE(COPD) IS A DISEASE STATE CHARACTERIZED BY AIRFLOW LIMITATION THAT IS NOT FULLY REVERSIBLE. THE AIRFLOW LIMITATION IS USUALLY BOTH PROGRESSIVE AND
More information意思是工作的法則 目 標是以操作者作中心 根據人體的能力設計最適合人體使用的工作間 器 材 工具及工作方法等 以提高生產力及工作效率 簡化工作程序及減少 出錯甚至是發生工傷意外的機會 除了應用於工業之外 人體工效學亦可適用於辦 公室 以提供一個安全 健康及舒適的工作環境予文職系人員
第34期 Issue 34 2010年2月 2.2010 言 引 Introduction 人體工效學 Ergonomics 一詞源於希臘文 意思是工作的法則 目 標是以操作者作中心 根據人體的能力設計最適合人體使用的工作間 器 材 工具及工作方法等 以提高生產力及工作效率 簡化工作程序及減少 出錯甚至是發生工傷意外的機會 除了應用於工業之外 人體工效學亦可適用於辦 公室 以提供一個安全 健康及舒適的工作環境予文職系人員
More information(omalizumab) 風濕免疫科 林科名醫師
Xolair @ (omalizumab) 風濕免疫科 林科名醫師 20150512 生物製劑命名學 生物製劑依其製造機轉而有不同的命名字尾 : 1. cept: 以生物科技將特殊受體與人體 IgG1 之 Fc part 融合者稱之 2. mab: 指單株抗體 (monoclonal antibody) 3. ximab: 指部分結構源自於動物的嵌合式單株 抗體 (chimeric monoclonal
More informationAsia Pac J Clin Nutr 2007; 16 (1):
Asia Pac J Clin Nutr 7; 16 (1):25-29 25 Original Article Reduction of adipose tissue and body weight: effect of water soluble calcium hydroxycitrate in Garcinia atroviridis on the short term treatment
More information法人說明會年度報告 陳念宜副總經理
法人說明會年度報告 2016.07.19 陳念宜副總經理 免責聲明 2 The statements and contents included in this presentation that are not historical in nature are forward-looking statements. These forwardlooking statements, which may
More information接觸者調查與預防性投藥 江振源. Director, Department of Lung Health and NCDs. 2011/04/29, National Taiwan University Hospital. Highlights of this presentation
接觸者調查與預防性投藥 江振源 Director, Department of Lung Health and NCDs 2011/04/29, National Taiwan University Hospital Highlights of this presentation Contact examination in the context of National Tuberculosis
More informationSurgical Management of Complete Rectal Prolapse. Purpose. To review our experience in the surgical management of complete
J Soc Colon Rectal Surgeon (Taiwan) December 2007 Original Article Surgical Management of Complete Rectal Prolapse Chung-Chi Huang Hong-Hwa Chen Shung-Eing Lin Chia-Lo Chang Chien-Chang Lu Wang-Hseng Hu
More information10 Year Experience of Iatrogenic Colon Perforation: Clinical Presentation and Management
J Soc Colon Rectal Surgeon (Taiwan) December 2010 Case Analysis 10 Year Experience of Iatrogenic Colon Perforation: Clinical Presentation and Management Yan-Jiun Huang 1 John Huang 2 Jin-Tung Liang 2 1
More informationUse of evidence-based medicine to choose contrast enhancing agents (iso-osmolar versus low-osmolar contrast media) for CT
. 弘光學報 64 期. Use of evidence-based medicine to choose contrast enhancing agents (iso-osmolar versus low-osmolar contrast media) for CT Ping-Liang Chen Yuan-Lin Lee Hui-Luu Zhan Hung-Chih Lai * Department
More information藥品新增 新藥介紹. <28D045>Desmopressin (Minirin Melt) (60ug) 凍晶口溶錠.
Desmopressin (Minirin Melt) (60ug) 凍晶口溶錠. Desmopressin (Minirin Melt) (60ug) 凍晶口溶錠. 藥理作用 / 不良反應 Synthetic analogue of the antidiuretic hormone arginine vasopressin. In a dose dependent
More information第二節課 : EBP ( Q / S / A / P / O )
第二節課 : EBP ( Q / S / A / P / O ) 郭集慶 腫瘤內科 緩和醫學科 癌症防治中心 實證醫學推動小組 光田綜合醫院 Evidence-based Practice 1. 應以病人 人口和實驗室作為健康照護決策的依據 2. The problem determines the nature and source of evidence to be sought, rather
More information( 計畫名稱 ) 第一型糖尿病人之癌症風險以及低血糖導致大血管疾病之風險
附件一 行政院國家科學委員會補助專題研究計畫 期中進度報告 期末報告 ( 計畫名稱 ) 第一型糖尿病人之癌症風險以及低血糖導致大血管疾病之風險 計畫類別 : 個別型計畫 整合型計畫 計畫編號 :MOST 104-2314-B-006-020 -MY2 執行期間 :2015 年 8 月 1 日至 2017 年 7 月 31 日 執行機構及系所 : 國立成功大學醫學系公共衛生科暨研究所 計畫主持人 :
More informationHong Kong College of Radiologists Palliative Medicine Training Programme
Hong Kong J Radiol. 2017;20:227-31 DOI: 10.12809/hkjr1716802 ORIGINAL ARTICLE Hong Kong College of Radiologists Palliative Medicine Training Programme LCY Lui 1, KH Wong 2, R Ngan 2, SWK Siu 3, E Chow
More informationHerpes Zoster. Chang Gung Hospital 2014/01/22 Yi-Chun Tsai
Herpes Zoster Chang Gung Hospital 2014/01/22 Yi-Chun Tsai Outline Introduction Clinical manifestation Epidemiology Pathophysiology Diagnosis Recurrent zoster Treatment Complications Pregnancy Zoster vaccune
More information個案評估 黃安君醫師 台北榮總高齡醫學中心
個案評估 黃安君醫師 台北榮總高齡醫學中心 1 長命 好命 平均餘命 - 失能年數 = 健康餘命 約有 8 年是不健康狀況可能需要住院或長期醫療 女性 < 男性 2 台灣老人成功與活躍老化之健康餘命探討, 林正祥, 2013 老年人的健康觀點 世界衛生組織說 衡量老年人健康最好的指標是功能 身心的健康程度比疾病的數目更能反映出老年人健康與否, 也決定醫療支出的多寡 3 Hazzard WR, eds.
More informationCentral Nervous System Tumor 楊智清
Central Nervous System Tumor 楊智清 TABLE 2. Histopathologic typing of central nervous system tumors:who classification Tumors of neuroepithelial tissue Astrocytic tumors (astrocytoma, glioblastoma, pilocytic
More informationEfficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2 positive breast cancer
Original Article Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2 positive breast cancer Winnie Yeo *, MY Luk, Inda S Soong, Tony YS Yuen, TY Ng,
More information宫颈上皮内瘤变 ; IgG1 IgG2 亚类 ; 酶联免疫吸附试验 R A (2009)
2009 年第 19 卷第 11 期 CHINA ONCOLOGY 2009 Vol.19 No.11 831 免疫球蛋白 G(immunoglobulin G,IgG) 是血清和细胞外液中含量最高的免疫球蛋白, 其某个亚类的升高, 可能与宫颈上皮内瘤变 (cervical intraepithelial neoplasia, CIN) 的发生 发展及转归有密切相关 然而对于 CIN 患者血清人乳头瘤病毒样颗粒
More informationZOMETA 用藥須知 ZOMETA 可用於減少和延緩因癌症 * 細胞由身體其他部位擴散至骨骼而引起的嚴重骨骼問題 1
ZOMETA 用藥須知 ZOMETA 可用於減少和延緩因癌症 * 細胞由身體其他部位擴散至骨骼而引起的嚴重骨骼問題 ZOMETA 是一種二碳磷酸鹽化合物 (bisphosphonate) 類藥物 它不屬於化療 ZOMETA 應每隔三至四週使用一次, 用以預防嚴重骨骼問題 ZOMETA 採用靜脈注射 通常最少需要 5 分鐘, 甚至更長時間 了解哪些癌症可以擴散至骨骼或 ZOMETA 療法的更多資訊,
More information運動對糖尿病的影響 ( 一 ) 運動對糖尿病的影響 ( 二 ) 運動對糖尿病的影響 ( 三 ) Prevention of T2DM. Exercise Prescription and Dietary Control for Diabetes Mellitus and Obesity
Exercise Prescription and Dietary Control for Diabetes Mellitus and Obesity CC Chow Department of Medicine & Therapeutics Prince of Wales Hospital Prevention of T2DM In people with IGT, a program of weight
More information在一所巿區急症室內評估分流心電圖方案的角色
Hong Kong Journal of Emergency Medicine Evaluating the role of a triage electrocardiogram protocol at an urban emergency department 在一所巿區急症室內評估分流心電圖方案的角色 BL Lim 林明良, A Vasu, GH Lim 林義賢 Objective: Our emergency
More informationCase Conference. Basic Information. Chief Complaint PMH PDH. 2013/06/22 台南奇美醫院 Reporter: 黃鈺芬醫師. Gender: female Age: 68 y/o Attitude: philosophical
Case Conference Basic Information 2013/06/22 台南奇美醫院 Reporter: 黃鈺芬醫師 Gender: female Age: 68 y/o Attitude: philosophical Chief Complaint Pus discharge over upper anterior area for several days PMH PDH Hypertension
More informationDrug-Drug Interactions 台大醫院藥劑部 林美淑藥師 / 副主任
Drug-Drug Interactions 台大醫院藥劑部 林美淑藥師 / 副主任 Limitations of clinical trials Short study period Small sample size Control environments, e.g. simple regimen DDIs are difficult to find Definition of drug-drug
More informationRenal Cell Carcinoma in a 3 year-old Girl: a case report
中華放射醫誌 Chin J Radiol 2008; 33: 271-275 271 Renal Cell Carcinoma in a 3 year-old Girl: a case report Kun-Shuo Huang 1 Shin-Lin Shih 1,2 Fei-Shih Yang 1,3 Department of Radiology 1, Mackay Memorial Hospital
More information臺北巿立大學 103 學年度研究所碩士班入學考試試題
班 臺北巿立大學 103 學年度研究所碩士班入學考試試題 別 : 共同科目 科目 : 語文 ( 英文 ) 考試時間 :90 分鐘 ( 含國文答題時間 ) 10:30-12:00 總分 :100 分 ( 國文 50 分 英文 50 分 ) 注意 : 不必抄題, 作答時請將試題題號及答案依照順序寫在答卷上 ; 限用藍色或黑色筆作答, 使用其他顏色或鉛筆作答者, 所考科目以零分計算 ( 於本試題紙上作答者,
More informationCytomegalovirus Colitis in an Immunocompetent Patient: Report of a Case and Review of the Literature
J Soc Colon Rectal Surgeon (Taiwan) March 2008 Case Report Cytomegalovirus Colitis in an Immunocompetent Patient: Report of a Case and Review of the Literature Mong-Wei Lin Jin-Tung Liang King-Jen Chang
More information